A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA

Supportive Care in Cancer

Volumn 19, Issue 6, 2011, Pages 833-841

  Barton, Debra L ^a   Wos, Edward J ^b   Qin, Rui ^a   Mattar, Bassam I ^c   Green, Nathan Benjamin ^d   Lanier, Keith S ^e   Bearden III, James Dewitt ^f   Kugler, John W ^g   Hoff, Kay L ^h   Reddy, Pavan S ^c   Rowland Jr , Kendrith M ⁱ   Riepl, Mike ^j   Christensen, Bradley ^a   Loprinzi, Charles L ^a  

^a Mayo Clinic   (United States)

^b SANFORD RESEARCH   (United States)

^c WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^d MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^e Providence Oncology and Hematology Care Clinic   (United States)

^f Gibbs Cancer Center and Research Institute   (United States)

^g Illinois Cancer Care   (United States)

^h Cancer Resource Center   (United States)

ⁱ Carle Cancer Center CCOP   (United States)

^j Gateway Health Mart Pharmacy   (United States)

more..

Author keywords

BAK PLO; CIPN; Topical gel

Indexed keywords

AMITRIPTYLINE; ANTINEOPLASTIC AGENT; BACLOFEN; CISPLATIN; KETAMINE; OXALIPLATIN; PLACEBO; TAXANE DERIVATIVE; THALIDOMIDE; VINCA ALKALOID; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR AFFECTING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; PHOSPHATIDYLCHOLINE; POLOXAMER;

ADULT; AGED; ARTICLE; CANCER PAIN; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFECT; FEMALE; HAND; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR SYSTEM; MUSCLE CRAMP; NAUSEA; NEUROPATHIC PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SKIN IRRITATION; SKIN TINGLING; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GEL; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADRENERGIC UPTAKE INHIBITORS; AGED; AMITRIPTYLINE; ANTINEOPLASTIC AGENTS; BACLOFEN; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GABA-B RECEPTOR AGONISTS; GELS; HUMANS; KETAMINE; LECITHINS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; POLOXAMER; TREATMENT OUTCOME;

EID: 80051670484     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0911-0     Document Type: Article

References (44)

1. Cavaletti G, Bogliun G, Marzorati L et al (1995) Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin. Cancer 75:1141-1150
2. Cavaletti G, Fabbrica D, Minoia C et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9:443-447 (Pubitemid 28273039)
3. Ocean JA, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12:619-625 (Pubitemid 39280311)
4. Pace A, Bove L, Aloe A et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18:73-79 (Pubitemid 27238776)
5. Rowinsky EK, Chaudry V, Cornblath DR et al (1993) Neurotox-icity of taxol. J Natl Cancer Inst Monogr 15:107-115
6. Verstappen C, Heimans JJ, Hockman K et al (2003) Neurotoxic complications of chemotherapy in patients with cancer. Drugs 63 (15):1549-1563
7. Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 5:565-571 (Pubitemid 30028616)
8. Campana WM, Eskeland N, Calcutt NA et al (1998) Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 19:237-244 (Pubitemid 28150974)
9. Cliffer KD, Siuciak JA, Carson SR et al (1998) Physiological characterization of taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 43:46-55 (Pubitemid 28124648)
10. Guastalla JP, Pujade-Lauraine E, Weber B (1998) Efficacy and safety of paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. Ann Oncol 9(9):37-43 (Pubitemid 28125762)
11. Polomano RC, Bennett GJ (2001) Chemotherapy-evoked peripheral neuropathy. Pain Medicine 2:8-14
12. Pujude-Lauraine E, Guastalla JP, Weber B et al (1997) Efficacy and safety of the combination of paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des investigateurs Nationauz pour l'etude des cancers ovariens phase II study. Semin Oncol 24:S15-30-S15-35 (Pubitemid 27451129)
13. Quasthoff S, Hartung HP (2002) Chemotherapy induced peripheral neuropathy. J Neurol 249:9-17
14. Envig AI, Wiernik PH, Wadler S et al (1998) Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (g-csf) in patients with unresectable malignany. Invest New Drugs 16:29-36 (Pubitemid 28379413)
15. LoMonaco M, Milone M, Batocchi AP et al (1992) Cisplatin neuropathy: clinical course and neurophysiologic findings. J Neurol 239:199
16. Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL (2008) Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol 26:(abstr 4009)
17. Ahmad M, Goucke CR (2002) Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 19 (12):929-945 (Pubitemid 36092254)
18. Argoff CE, Katz N, Backonja M (2004) Treatment of postherpetic neuralgia:a review of therapeutic options. J Pain Symptom Manage 28(4):396-411 (Pubitemid 39313169)
19. Jensen PG, Larson JR (2001) Management of painful diabetic neuropathy. Drugs Aging 18(10):737-749 (Pubitemid 33135196)
20. Hammack JE et al (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98(1-2):195-203 (Pubitemid 34722482)
21. Rao RD, Michalak JC, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110 (9):2110-2118 (Pubitemid 350036873)
22. Rao RD, Flynn PJ, Sloan J et al (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double blind, placebo controlled NCCTG trial, N01C3. Cancer 112(21):2802-2808 (Pubitemid 351969227)
23. Moore DH, Donnelly J, McGuire WP et al (2003) Limited access trial using amifostine for protection against cisplatin-and three-hour paclitaxel-induced neurotoxicity: a phase ii study of the Gynecologic Oncology Group. J Clin Oncol 21(22):4207-4213 (Pubitemid 46606190)
24. Vahdat L, Papadopoulos K, Lange D et al (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192-1197 (Pubitemid 32708669)
25. Baron (2006) Mechanisms of disease: neuropathic pain, a clinical perspective. Nat Clin Pract Neurol 2(2):95-106 (Pubitemid 43210250)
26. Jones M (2000) Chronic neuropathic pain: pharmacological interventions in the new millennium. Int J Pharm Comp 4(1):6-15
27. Sawynok J (2005) Topical analgesics in neuropathic pain. Curr Pharm Des 11(23):2995-3004 (Pubitemid 41158088)
28. Sawynok J (2003) Topical and peripherally acting analgesics. Pharmacol Rev 55:1-20 (Pubitemid 36268396)
29. Lynch ME, Clark AJ, Sawynok J (2003) A pilot study examining topical amitriptyline, ketamine and a combination of both in the treatment of neuropathic pain. Clin J Pain 19:323-328 (Pubitemid 37075674)
30. Lynch ME, Clark AJ, Sawynok J, Sullivan MJL (2005) Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes. Anesthesiology 103(1):140-146
31. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ (2005) Topical amitriptyline and ketamine in neurotopical amitriptyline and ketamine in neuropathic pain syndromes: an open label study. J Pain 6(10):644-649 (Pubitemid 41395055)
32. Lockhart E (2004) Topical combination of amitriptyline and ketamine for post herpetic neuralgia. J Pain 5:S182
33. Everton D, Bhagwat D, Damask M (2007) An open-label pharmacokinetic study in humans of a 4% amitriptyline, 2% ketamine topical cream. J Pain 8(4 suppl 1):S48
34. Ceschel G, Bergamante V, Maffei P et al (2005) Solubility and transdermal permeation properties of dehydroepiandrosterone cyclodextrin complex from hydrophilic and lipophilic vehicles. Drug Delivery 12:275-280 (Pubitemid 41356183)
35. B receptor agonist baclofen has non-specific antinociceptive effect in the model of peripheral neuropathy in the rat. Pysiol Res 53:351-355 (Pubitemid 38797292)
36. Smith GD, Harrison SM, Birch PJ et al (1994) Increased sensitivity to the antinociceptive activity of±baclofen in an animal model of chronic neuropathic, but not chronic inflammatory hyperalgesia. Neuropharmacology 33:1103-1108 (Pubitemid 24306635)
37. Gammaitoni A, Gallagher RM, Welz-Bosna M (2000) Topical ketamine gel: possible role in treating neuropathic pain. Pain Medicine 1(1):97-100
38. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115
39. Postma TJ, Aaronson NK, Heimans JJ, EORTC Quality of Life Group et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135-1139 (Pubitemid 40725571)
40. McNair DM, Loor M, Droppleman LF (2003) Profile of mood states manual. Multi-Health Systems, New York
41. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 23(2):129-138
42. Sloan JA, O'Fallon JR, Suman VJ et al (1998) Incorporating quality of life measurement into oncology clinical trials. Proc Am Stat Assoc 1998:282-287
43. Grunberg SM, Groshen S, Steingass S (1996) Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 5:65-72 (Pubitemid 26100504)
44. Gudex C, Dolan P, Kind P (1996) Health state valuations from the general public using the visual analogue scale. Qual Life Res 5:521-531 (Pubitemid 27006964)